Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Adherium Ltd. ( (AU:ADR) ).
Adherium Limited has appointed Victoria Durrans as a director of the company, effective 4 March 2026, in accordance with ASX listing rule disclosure requirements. The company disclosed that Durrans currently holds no relevant interests in Adherium securities and has no interests in any related contracts, indicating a neutral equity position at the commencement of her board tenure.
The appointment signals a refresh of Adherium’s board composition, with governance disclosures confirming full compliance with director interest reporting standards. While no further operational details were released, the clean interest profile may be viewed positively by investors focused on independence and transparency in the company’s governance framework.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is a listed company on the ASX, operating in the healthcare and medical technology sector. The company focuses on developing and commercialising digital health solutions, including connected devices and related services designed to support medication adherence and remote monitoring for patients and clinicians.
Technical Sentiment Signal: Sell
Current Market Cap: A$13.03M
For detailed information about ADR stock, go to TipRanks’ Stock Analysis page.